The
primary treatment for malignant tumors remains to be resection.
The strongest predictor of recurrence and postoperative prognosis
is whether diseased tissue/cells remain(s) at the surgical margin.
Cancer surgery entails surgeons having the capability to visually
distinguish between subtle shades of color in attempts of differentiating
between diseased tissue and healthy tissue under standard white-light
illumination, as such tissue states appear identical at the meso-/macroscopic
level. Accordingly, enhancing the capability of surgeons to do so
such that they can accurately delineate the tumor margin is of paramount
importance. Fluorescence-guided surgery facilitates in enhancing such
capability by color-coding the surgical field with overlaid contrasting
pseudo-colors from real-time intraoperative fluorescence emission
via utilizing fluorescent constructs in tandem. Constructs undergoing
clinical trials or that are FDA-approved provide peak fluorescence
emission in the visible (405 - 700 nm) or near-infrared-I (NIR-I)
spectral region (700–900 nm), whereby differentiation between
tissue states progressively improves in sync with using constructs
that emit longer wavelengths of light. Here, we repurpose the usage
of such fluorescent constructs by establishing feasibility of a tumor-targeting
immunoconjugate (cetuximab-IRDye800) having peak fluorescence emission
at the NIR-I spectral region to provide improved tumor margin delineation
by affording higher tumor-to-background ratios (TBRs) when measuring
its off-peak fluorescence emission at the near-infrared-II (NIR-II)
spectral region (1000–1700 nm) in in vivo applications.
We prepared murine tumor models, administered such immunoconjugate,
and imaged such models pre-/post-administration via utilizing imaging
systems that separately afforded acquisition of fluorescence emission
in the NIR-I or NIR-II spectral region. On doing so, we determined in vivo TBRs, ex vivo TBRs with/-out skin,
and ex vivo biodistribution, all via measuring the
fluorescence emission of the immunoconjugate at tumor site(s) at both
spectral regions. Collectively, we established feasibility of using
the immunoconjugate to afford improved tumor margin delineation by
providing 2-fold higher TBRs via utilizing the NIR-II spectral region
to capture off-peak fluorescence emission from a fluorescent construct
having NIR-I peak fluorescence emission.